echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Innovent's PI3Kδ inhibitor parsaclisib plans to be included in breakthrough treatment products

    Innovent's PI3Kδ inhibitor parsaclisib plans to be included in breakthrough treatment products

    • Last Update: 2021-03-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    March 22, Chinese State Drug Administration Bureau Center for Drug Evaluation (CDE) latest announcement, Cinda biological (HKSE stock code: 01801) PI3Kδ inhibitor parsaclisib oral breakthrough therapy has been incorporated into the proposed varieties, developing adaptation Symptoms are relapsed or refractory follicular lymphoma .


    Managing lymphoma

    Follicular lymphoma is a malignant tumor formed in the blood system, accounting for 22% of non-Hodgkin lymphoma (NHL) worldwide and 8.


    In December 2018, Innovent and Incyte reached a strategic cooperation on three drug candidates in clinical trials, including parsaclisib.


    In December 2020, in the Phase II clinical study of Innovent, eligible patients received 20 mg of Parsaclisib once a day for eight weeks, and then received 20 mg twice a week (Weekly Dosage Group [WG]) or daily A treatment plan of 2.


    Data source is believed to be the official website of Biology

    The data source is believed to be the official website of Biology

    It is reported that the world's first once-daily oral PI3K/CK1 inhibitor is TG's umbralisib (trade name UKONIQ), and it was approved by the U.


    FDA leaves a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.